Trial Profile
Phase I/II proof-of-principal trial of Pepscan's anti-GnRH prostate cancer vaccine in patients with hormone-refractory prostate cancer
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 03 Oct 2006
Price :
$35
*
At a glance
- Drugs Prostate cancer vaccine (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pepscan Therapeutics
- 03 Oct 2006 New trial record.